$EPAZ News! Epazz ZenaPay Files a Patent for Blockchain

New Post Public Reply Private Reply Replies (0) Message Board
trooperstocks
178
$EPAZ News! Epazz ZenaPay Files a Patent for Blockchain Fantasy Sport Gambling Solution to Manage Compliance and Verification of Transaction to Benefit from Supreme Court Decision
Recent Supreme Court Decision Creates Need to Manage Multiple Different State Laws for Online Sports Gambling

CHICAGO, IL - (NewMediaWire) - June 20, 2018 - Epazz, Inc. (OTC: EPAZ), a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions, has announced that it has filed a provisional patent for a blockchain Fantasy Sport Gambling Solution. Because the recent Supreme Court decision resulted in fifty separate state laws, the average individual will not have time to look up each state law to determine if he or she is in compliance.

Part of the patent application focuses on compliance management and verification of available funds. Before a person is able to participation in a transaction, ZenaPay will verify all the details in the background. The transactions will be run through the Ether network and will be posted on the user’s profile.

In October 2017, and prior to the release of ZenaPay, Epazz announced that it saw an opportunity for ZenaPay in fantasy sports during the design process for ZenaPay’s Fantasy Sport Gambling Solution. The design team developed a unique way to process transactions to verify that the bidder had the funds available and was in compliance with state laws.

Epazz CEO, Shaun Passley, Ph.D., said, “We are able to reuse our technology in multiple different blockchain applications. We believe we need to create a primary mobile app which has robust functionality. The user will be able to select which functions he or she wants. This business model allows us to decrease our customer acquisition cost and build a user community as we develop and acquire new apps.”

About ZenaPay (www.ZenaPay.com)

Epazz is developing ZenaPay to solve a major problem in high-risk industries: getting paid. Traditional banking systems do not allow high-risk industries to access their payment systems. ZenaPay offers a cutting-edge payment solution that gives consumers a way to buy items online or in stores using Bitcoin. The new Bitcoin payment software will allow consumers to use digital currency to make online or in-store purchases with ease. The process will be anonymous because all transaction details will be encrypted through Bitcoin, which will enable stores to accept digital currency instead of only cash. ZenaPay is available on the App Store and Play Store.

About Epazz, Inc. (www.epazz.com)

Epazz, Inc. is a leading cloud-based software company that specializes in providing customized cloud applications to the corporate world, higher-education institutions and the public sector. Epazz BoxesOS™ v3.0 is the complete business web-based software package for small- to mid-size businesses, Fortune 500 enterprises, government agencies and higher-education institutions. BoxesOS provides many of the web-based applications organizations would otherwise need to purchase separately. Epazz’s other products are DeskFlex™ (room scheduling software) and DeskFlex™ (an applicant-tracking system).

SAFE HARBOR

This is the “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: Certain statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by the use of forward-looking statements such as “may,” “expect,” “intend,” “estimate,” “anticipate,” “believe” and “continue” (or the negative thereof) or similar terminology. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results or those implied by such forward-looking statements. Investors are cautioned that any forward-looking statements are not guarantees of future performance and that actual results may differ materially from those contemplated by such forward-looking statements. Epazz, Inc. assumes no obligation and has no intention of updating these forward-looking statements, and it has no obligation to update or correct information prepared by third parties that is not paid for by Epazz, Inc. Investors are encouraged to review Epazz, Inc.’s public filings on SEC.gov and otcmarkets.com, including its unaudited and audited financial statements and its OTC market's filings, which contain general business information about the company’s operations, results of operations and risks associated with the company and its operations.

CONTACT:
Epazz,Inc.
Investor Relations
investors@epazz.net
(312) 955-8161
www.epazz.com

Source: Epazz, Inc.

https://app.newmediawire.com/news/5b299e4becf...ce=twitter
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.

1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.

4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aroa Biosurgery Reports Low Infection Rates: A Milestone

Updated Category News Views 1

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 3

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Clover's RSV Combo Vaccine Shows Promise in Trials

Updated Category News Views 1

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 12

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
ATTACK SHARK Partners with Cloud9 League Team

Updated Category News Views 2

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Continue Reading
Zendure, SolarFlow Pro Win Big at IFA 2026 Tech Awards

Updated Category News Views 2

Trophy Time for Zendure in Berlin The Berlin Chronicles of 2026 tell an interesting tale for Zendure—a tale where top honors and glowing recognition highlight its efforts in the sustainable energy arena. At the Global Product Technology Innovation Awards, Zendure's SolarFlow 4000 Mix Pro snagged the Gold for Sustainable Home Energy Storage System. Not only that, but...

Continue Reading
Media Forum Spotlights Asia-Pacific Cooperation

Updated Category News Views 3

The Opening Scene: A Gathering with Purpose Well, here we go, diving right into the latest shindig in Shenzhen at the Asia-Pacific Media Forum. Held in China's Guangdong province, they've rounded up over 400 reps from every corner of the globe, all chewing over one key theme: "Building a Path to Shared Prosperity for the Asia-Pacific Community." You could say it's a step...

Continue Reading
Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 0

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading

Top 5 Most Recently Viewed Articles

Prologis Earnings Report: Investors' Key Insights and Analysis

Updated Category News Views 138

Understanding Prologis's Upcoming Quarterly Earnings Prologis (NYSE: PLD) is set to release its latest quarterly earnings report, and investors are eagerly awaiting the insights it will provide. As the company approaches its earnings announcement, analysts project an earnings per share (EPS) of $1.02, which serves as a benchmark for performance expectations. Investor...

Continue Reading
How Changing U.S. Jobs Report Affects Market Dynamics

Updated Category News Views 171

The recent U. S. employment report sent shockwaves through financial markets, reshaping how traders and investors eyed their portfolios. Stronger-than-expected job creation—with figures soaring over 100,000—meant one thing: the narrative on interest rates was about to change. Gone were the days of comfortably betting on rate cuts; now, everyone’s scrambling to...

Continue Reading
Suno Boosts Innovation for Creators by Acquiring WavTool

Updated Category News Views 157

Suno Boosts Innovation for Creators by Acquiring WavTool Suno has recently made a significant move in the music industry with their acquisition of WavTool. This strategic decision aims to enhance their offerings for songwriters and producers, enabling them to create music that resonates with a broader audience. By integrating WavTool's advanced capabilities into their...

Continue Reading
Leqembi's New IV Treatment Approval: A Milestone for Alzheimer’s Care

Updated Category News Views 274

Leqembi Approved for IV Maintenance Treatment BioArctic AB, a notable player in the biopharmaceutical sector, has made significant headlines with the approval of Leqembi (lecanemab) for intravenous (IV) maintenance treatment for Alzheimer’s disease in the United Kingdom. This groundbreaking decision was announced following rigorous evaluations by the Medicines and...

Continue Reading
Investors of ATYR, MLTX, BAX, and JHX Have Legal Options

Updated Category News Views 145

Overview of Class Action Lawsuits for ATYR, MLTX, BAX, JHX Attention investors! If you’ve invested in aTyr Pharma Inc. (NASDAQ: ATYR), MoonLake Immunotherapeutics (NASDAQ: MLTX), Baxter International, Inc. (NYSE: BAX), or James Hardie Industries plc (NYSE: JHX), it’s important to be aware of significant class action lawsuits affecting your investments. These companies...

Continue Reading